RxDoctor Payments Data

Mary Pena-Pridmore, MD

Family Medicine · Live Oak, CANPI 1336240837

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 126 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$306
  • Mannkind Corporation$277
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$213
  • Novo Nordisk$207
  • Daiichi Sankyo Inc.$199
  • Pfizer$147
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,377 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$192
Medicare patients
20
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$101,041
TrulicityDulaglutide36$51,133
JanuviaSitagliptin Phosphate43$37,629
EliquisApixaban24$25,330
FarxigaDapagliflozin Propanediol33$22,609
TradjentaLinagliptin26$22,015
MounjaroTirzepatide16$14,768
RybelsusSemaglutide12$14,671
OzempicSemaglutide16$14,417
Nurtec OdtRimegepant Sulfate11$12,532
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$9,174
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,764
Albuterol Sulfate HfaAlbuterol Sulfate105$3,451
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,209
Atorvastatin Calcium208$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$29$123,056136 claims
Lilly USA, LLCTrulicity, Mounjaro$128$65,90052 claims
PfizerEliquis, Nurtec Odt$147$37,86235 claims
MerckJanuvia$103$37,62943 claims
Novo NordiskRybelsus, Ozempic$207$29,08828 claims
AstraZenecaFarxiga$144$22,60933 claims
GSKShingrix$131$3,20918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Live Oak

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →